COVID-19 Respiratory Distress and Antithrombotic Drugs in Subject's Habits (CRASH)

University Hospital, Strasbourg, France

Status: Unknown

Conditions: Sars-CoV2

Study type: Observational

Funder types: Other

Identifiers

NCT04412473

7837

Details and patient eligibility

About

Current management of VID-19 consists of oxygen support without specific treatment. Hospitalization may suddenly require delayed resuscitation. This evolution corresponds to an atypical acute respiratory distress syndrome (ARDS), the mechanism of which is poorly understood and difficult to predict. The general pathophysiology of ARDS, the vascular tropism of SARS-Cov2, the description of coagulopathy and numerous pulmonary artery thromboses in resuscitation and the encouraging investigation of antithrombotics in general ARDS

Enrollment: 1,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Major Subject (≥18 years)
• Subject hospitalised in HUS or GHRMSA for COVID-19
• The diagnosis COVID-19 confirmed by smear or evoked by CT scan or chest X-ray without a differential diagnosis retained in the medical record
• Subjects who, after being informed, do not wish to have their data reused for the purposes of this research

Exclusion criteria

• Subject who expressed opposition to participating in the study
• Subject under guardianship or trusteeship
• Subject under safeguard of justice
• Patient hospitalized in a geriatric service or in a ward not labeled COVID (surgery, oncology,...) or in a short-term hospitalization unit without transfer to another service.
• Serious patient on admission to the emergency room and recused from resuscitation.